Navigation Links
Pain Relief For Osteoarthritis Patients

Osteoarthritis is a progressive, degenerative joint disease that affects more than 21 million people in the United States. The most common // symptoms are pain, stiffness, reduced joint range of motion and limitations to normal activities such as getting up from a chair, walking, balance and strength, and walking up and down stairs.

Pain-reducing medications such as acetaminophen, non-steroidal anti-inflammatory drugs and COX-2 inhibitors have been common treatments for osteoarthritis in the growing elderly population. However, these medications often have painful side effects or do not react well with other medications.

A new study shows the addition of menthol to topical creams provides significant pain relief and improvements in physical performance for people with osteoarthritis.

One proven alternative treatment is the use of oral and/or a topical blend of cetylated fatty acids. However recently researchers added menthol to this cream. Researchers assigned 10 patients with knee osteoarthritis, 10 with wrist osteoarthritis, and eight with elbow osteoarthritis to an experimental group based on the location of the diagnosed osteoarthritis. Each patient applied the cream to the affected area twice a day every day for one week.

It was observed that the topical cream with menthol produced significant improvements in physical performance and reduced pain from osteoarthritis of the knee, hip and elbow.
'"/>




Page: 1

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Relief from common back pain
3. Relief to pregnant women using fertility drugs
4. Relief of pain for suffering patients
5. Relief from cancer pain with anticonvulsants
6. Relief from Migraine
7. Relief From Migraines
8. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
9. Drug Found To Bring Relief For Individuals With Early Parkinson’
10. Relief For Women Suffering From Fibromyalgia
11. Lemons Could Give Relief For Patients Suffering From Asthma
Post Your Comments:
Breaking Medicine Technology:Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 2Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 3Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging 4Springer launches SpringerImages 9172 1Springer launches SpringerImages 9172 2Improving Care for Cardiac Patients is Centerpiece of American Society of Nuclear Cardiology Meeting 51101 1Improving Care for Cardiac Patients is Centerpiece of American Society of Nuclear Cardiology Meeting 51101 2American Optometric Association Supports New Federal Health Report Findings 3A Vision Screening Methods for Seniors are Lacking 51097 1American Optometric Association Supports New Federal Health Report Findings 3A Vision Screening Methods for Seniors are Lacking 51097 2American Optometric Association Supports New Federal Health Report Findings 3A Vision Screening Methods for Seniors are Lacking 51097 3
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3